Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Drug Profile

Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Alternative Names: Cell therapies for ophthalmic diseases - Shin Nippon Biomedical Laboratories (SNBL)/RIKEN; Induced pluripotent stem (iPS) cells for eye disorders - Shin Nippon Biomedical Laboratories; iPS cell-derived RPE cell transplantation for Age-related macular degeneration - Healios/Shin Nippon Biomedical Laboratories; iPSC-derived RPE sheet - RIKEN/Healios; Retinal pigment epithelial (RPE) cells for AMD - Healios/RIKEN

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RIKEN
  • Developer Healios; RIKEN; Shin Nippon Biomedical Laboratories
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Eye-Disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Intraocular, Injection)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Eye-disorders in Japan (Intraocular, Injection)
  • 02 Dec 2013 Retina Institute Japan is now called Healios
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top